A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs BGB 290 (Primary) ; Temozolomide (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
    • 30 Aug 2017 According to a BeiGene media release, results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 09 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top